https://www.selleckchem.com/pr....oducts/tideglusib.ht
Several other disease-modifying treatments are being studied in clinical trials. Selection criteria for patients at risk of rapid progression vary widely among countries and are based on a combination of age, baseline glomerular filtration rate (GFR), GFR slope, baseline TKV, and TKV rate of growth. This review details the approach in assessing the risk of disease progression in ADPKD and identifying patients who would benefit from long-term therapy with disease-modifying agents.Endoplasmic Reticulum (ER) stress signaling is an adapt
Like
Comment
Share
